nMSC and SEC therapies improve diastolic function in HFpEF through distinct remodeling mechanisms converging on T reg -mediated immune modulation. VIPcell supported identification of causal regulators, highlighting T reg -related signaling as a key driver of myocardial recovery in HFpEF. These findings offer mechanistic insight into cellular therapies for HFpEF and support the development of targeted, T reg -focused interventions.
Ge et al. (Fri,) studied this question.